You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Article metrics

Article menu

Download PDFPDF

XML
Review
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

 

Online download statistics by month:

Online download statistics by month: February 2020 to June 2025

AbstractFullPdf
Feb 2020415415304
Mar 2020609609305
Apr 2020310310246
May 2020321321157
Jun 2020326326151
Jul 2020331331166
Aug 2020295293141
Sep 2020402402184
Oct 2020481481212
Nov 2020435435158
Dec 2020439439150
Jan 2021545544240
Feb 2021442442186
Mar 2021497497183
Apr 2021502502182
May 2021602602180
Jun 2021439438146
Jul 2021388388135
Aug 2021315316122
Sep 2021658658183
Oct 2021475476192
Nov 2021388386141
Dec 2021351353148
Jan 202233434197
Feb 2022209217130
Mar 2022328345173
Apr 2022288315130
May 2022303317174
Jun 2022317333113
Jul 202222723793
Aug 2022198205112
Sep 2022265279137
Oct 2022282295115
Nov 2022302306119
Dec 202221221460
Jan 202317617879
Feb 2023209216114
Mar 202322622999
Apr 202313313571
May 202312312359
Jun 202316216270
Jul 202314814978
Aug 202318818976
Sep 202316116354
Oct 202325525858
Nov 202343643647
Dec 2023979834
Jan 2024818348
Feb 202414814827
Mar 2024116119144
Apr 202410911052
May 2024828326
Jun 202410910940
Jul 202414314744
Aug 202411211240
Sep 202412813151
Oct 202416516660
Nov 202416416854
Dec 202413914252
Jan 202512712854
Feb 202526726755
Mar 202522322370
Apr 202518018246
May 202515815842
Jun 202510110225
Total18097182827434